The HPV testing and Pap test market is expanding as healthcare systems place greater emphasis on cervical cancer prevention, early diagnosis, and accessible screening. The market was valued at USD 3.6 billion in 2025 and is projected to grow from USD 3.8 billion in 2026 to USD 6.2 billion by 2033, registering a 7.2% CAGR from 2026 to 2033. Technological advancements in testing products, the rising prevalence of cervical cancer, and government initiatives aimed at reducing disease burden are among the factors supporting market growth.

Download a free sample copy of the HPV Testing And Pap Test market report to understand detailed coverage and inclusions in the final report

Market Breakdown & Statistics

The market includes HPV DNA/RNA tests, Pap cytology tests, co-testing, laboratory services, screening consumables, and associated diagnostic instruments. These solutions are used across hospitals, diagnostic laboratories, physician offices, community health centers, and national screening programs. The Pap test segment led the type category with a 62.1% revenue share in 2025, supported by established screening infrastructure and widespread implementation.

HPV testing is expected to record the fastest CAGR of 8.2% during the forecast period. Increasing adoption of HPV DNA testing, higher sensitivity, and the growing use of HPV testing as a primary screening approach are supporting this expansion. Self-retrieved samples are also gaining attention as healthcare systems explore ways to make screening more accessible and comfortable for eligible women.

By application, cervical cancer represented the largest segment, accounting for 77.6% of revenue in 2025. The segment is also anticipated to grow at the fastest CAGR during the forecast period, supported by higher incidence compared with vaginal cancer and increasing investments in screening and diagnostic technologies.

The Pap test and HPV test product category held the largest share at 62.1% in 2025. Repeated screening requirements and continued development of assays and kits contribute to product demand. Services are expected to witness the fastest CAGR, supported by self-administered and at-home HPV screening services, telehealth platforms, and partnerships between diagnostic companies and healthcare providers.

PCR accounted for the largest technology share at 40.0% in 2025. Its adoption is supported by established use in HPV screening and the cost-effectiveness of these tests compared with some newer molecular diagnostics and immunoassays. PCR is also expected to witness the fastest CAGR as DNA-based HPV testing becomes increasingly incorporated into screening strategies.

Hospitals and clinics represented the leading end-use segment with a 43.1% revenue share in 2025. High patient volumes, improving healthcare infrastructure, and increasing healthcare expenditure are supporting the adoption of technologically advanced screening and diagnostic solutions in these settings. Laboratories also play an important role by processing high testing volumes through centralized and increasingly automated workflows.

Key Market Drivers & Disruptions

The rising burden of cervical cancer and increasing HPV prevalence are major market drivers. The source notes that approximately 660,000 women were diagnosed with cervical cancer in 2022 and about 350,000 died from the disease. Persistent infection with high-risk HPV is closely associated with cervical cancer, creating continued demand for routine screening, HPV testing, and Pap tests.

Government screening initiatives and growing disease awareness are further influencing testing volumes. Organizations and healthcare authorities are increasing awareness around cervical cancer prevention, while screening guidelines continue to evolve toward HPV-first and molecular testing approaches. These initiatives are helping expand the role of preventive diagnostics.

At the same time, limited screening participation remains a significant market restraint. Low awareness, social stigma, healthcare access disparities, and inconsistent screening adherence can prevent eligible women from receiving routine testing. These challenges are particularly relevant in underserved populations where screening infrastructure and access to women's healthcare remain limited.

Self-sampling and home-based screening represent an important opportunity. Conventional screening can face barriers associated with discomfort, scheduling, limited access to gynecological services, and social stigma. Self-collected HPV samples can help address some of these barriers by enabling sample collection at home or in non-clinical settings followed by laboratory-based analysis.

Geographic Region

North America dominated the market with a 41.2% revenue share in 2025 and is projected to maintain its leading position throughout the forecast period. High awareness of early cervical cancer diagnosis, established screening guidelines, and favorable healthcare reimbursement are supporting market development. The U.S. held the largest market share in 2025.

Asia Pacific is expected to register the fastest CAGR of 9.0% during the forecast period. Rising cervical cancer incidence, expanding government screening programs, greater accessibility to molecular diagnostics, and awareness initiatives are contributing to market expansion. China dominated the Asia Pacific market in 2024 and is expected to register the fastest CAGR over the forecast period.

Europe also holds a significant position, supported by public health initiatives, updated screening guidelines, molecular diagnostics, self-sampling programs, and AI-assisted cytology. The broader market outlook is therefore shaped by the combination of established screening infrastructure, emerging diagnostic technologies, and efforts to improve screening accessibility.

Key HPV Testing And Pap Test Companies:

Abbott.
QIAGEN
BD.
Quest Diagnostics Incorporated

Explore the full list of profiled companies operating in this market with recent strategic initiatives

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Self-Sampling and PCR Are Creating Fresh HPV Testing Market Opportunities

The global HPV testing and pap test market size was valued at USD 3.6 billion in 2025 and is projected to grow from USD 3.8 billion in 2026 to USD 6.2 billion